Frontier Science Foundation-Hellas
Frontier Science Foundation-Hellas is recorded as a service provider in 8 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 8 of 8 trials · Latest update first
ETOP 23-22 RAISE: A single-arm phase II trial of the addition of niraparib to anti-PD-L1 antibody maintenance in patients with SLFN11-positive, extensive-disease small cell lung cancer.
Sponsor ETOP IBCSG Partners Foundation
- Start (EU)
- Latest update
- Estimated end
ETOP 27-23 ARCH – A randomised phase III trial of adjuvant cemiplimab in patients with resected stage IIA-IIIB NSCLC who have not received prior adjuvant chemotherapy.
Sponsor ETOP IBCSG Partners Foundation
- Start (EU)
- Latest update
- Estimated end
ETOP 21-21 BOUNCE: A multicentre, randomised, phase II trial of brigatinib consolidation versus observation or durvalumab in patients with unresectable stage III NSCLC and ALK-rearrangement, after definitive chemo-radiotherapy.
Sponsor ETOP IBCSG Partners Foundation
- Start (EU)
- Latest update
- Estimated end
ETOP 18-21 AMAZE-lung: A multicentre single-arm phase II trial of amivantamab, lazertinib plus bevacizumab in patients with EGFR-mutant advanced NSCLC with progression on previous third-generation EGFR-TKI.
Sponsor ETOP IBCSG Partners Foundation
- Start (EU)
- Latest update
- Estimated end
ETOP 25-23 ADOPT-lung: An international, multicentre, open-label randomised phase III trial to evaluate the benefit of adding adjuvant durvalumab after neoadjuvant chemotherapy plus durvalumab in patients with stage IIB-IIIB (N2) resectable NSCLC
Sponsor ETOP IBCSG Partners Foundation
- Start (EU)
- Latest update
- Estimated end
ETOP 22-22 ADEPPT: A multicentre, single-arm phase II trial of adagrasib in patients with KRASG12C-mutant NSCLC, including the elderly (≥70 years) or patients with poor performance status
Sponsor ETOP IBCSG Partners Foundation
- Start (EU)
- Latest update
- Estimated end
ETOP 29-25 START-lung: A multicentre phase II trial of tarlatamab in patients with pretreated extensive-stage small cell lung cancer (ES-SCLC) and ECOG PS 2.
Sponsor ETOP IBCSG Partners Foundation
- Start (EU)
- Latest update
- Estimated end
ETOP 14-18 CHESS: A multicentre single arm phase II trial assessing the efficacy of immunotherapy, chemotherapy and stereotactic radiotherapy to metastases followed by definitive surgery or radiotherapy to the primary tumour, in patients with synchronous oligo-metastatic non-small cell lung cancer
Sponsor ETOP IBCSG Partners Foundation
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Frontier Science Foundation-Hellas?
The 2026-10-09 snapshot links Frontier Science Foundation-Hellas to 8 distinct CTIS trials. Recorded services include Statistical analysis, Medical writing. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Frontier Science Foundation-Hellas?
The most frequently recorded therapeutic areas are Solid Tumor Oncology, Respiratory. Recorded phases include Phase 2, Phase 3. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Frontier Science Foundation-Hellas conducted?
The linked trials record locations in 12 countries, including Italy, Spain, France, Ireland, Netherlands. These are trial locations, not confirmed office locations or countries where Frontier Science Foundation-Hellas delivered services.
What can this page tell me about Frontier Science Foundation-Hellas's trial experience?
Browse 8 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Frontier Science Foundation-Hellas. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Frontier Science Foundation-Hellas